| abstract |
The disclosure provides compositions and methods for determining the likely clinical outcomes of Asian cancer patients treated with a therapy comprising an anti-VEGF antibody by screening for genotypes of one or more of VEGFR2 rsl2505758 T/C, VEGF-A rs699946 A/G, or VEGF- A rs699947 A/C polymorphism. After determining if a patient is likely to be successfully treated, the disclosure also provides methods for treating the patients. |